Skip to main content

Volume 3 Supplement 2

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

  • Poster presentation
  • Open access
  • Published:

Cish actively silences tcr signaling in CD8+ T cells to maintain tumor tolerance


Improving the functional avidity of effector T cells is critical in overcoming inhibitory factors within the tumor microenvironment and eliciting tumor regression.


We have found that Cish, a member of the Suppressor of Cytokine Signaling (SOCS) family, is induced by TCR stimulation in CD8+ T cells and inhibits their functional avidity against tumor.


Genetic deletion of Cish in CD8+ T cells enhances their expansion, functional avidity and cytokine polyfunctionality, resulting in pronounced and durable regression of established tumors. Although Cish is commonly thought to block STAT5 activation, we found that the primary molecular basis of Cish suppression is through inhibition of TCR signaling. Cish physically interacts with the TCR intermediate PLCg1, targeting it for proteasomal degradation following TCR stimulation. Furthermore we extend these findings to patients PBL retrovirally transduced with tumor-specific TCRs and shorthairpin microRNAs targeting CISH.


These findings establish a novel targetable interaction that regulates the functional avidity of tumor-specific CD8+ T cells and can be manipulated to improve adoptive cancer immunotherapy.

Author information

Authors and Affiliations


Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Palmer, D., Guittard, G., Franco, Z. et al. Cish actively silences tcr signaling in CD8+ T cells to maintain tumor tolerance. j. immunotherapy cancer 3 (Suppl 2), P39 (2015).

Download citation

  • Published:

  • DOI: